Long-Lasting Pain Relief Without Opioids: New Local Treatment for Chronic Pain

Chronic Pain Concept

The research also demonstrates that males and females experience pain differently.

An investigation into the origins of the sensation of pain has led to the development of a novel and durable treatment for inflammatory pain that could be a promising alternative to opioids. The preclinical research was conducted by neuroscientists and pharmacologists, all in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. It was published today (October 4, 2021) in Nature Communications.

The research has led to UB filing patents on two sets of novel lipidated peptides — peptides modified with lipid molecules — that are injected at the site of injury. With the assistance of UB Business and Entrepreneurial Partnerships, the researchers have also formed a startup company called Channavix, Inc. that is developing non-opioid drugs for pain to assist in commercialization.

“Our small peptides are able to penetrate nerve endings and provide long-lasting pain relief after a single administration,” said senior author Arin Bhattacharjee, PhD, associate professor of pharmacology and toxociology in the Jacobs School.

The UB researchers had been investigating sensory neurons called nociceptors, which activate in response to pain caused by injury.

Informing the brain

“Pain is usually considered a symptom of injury,” said Bhattacharjee. “Pain neurons transmit their information to the brain, informing the brain of both the location of the injury and the severity of the injury. At the molecular level, our research is helping unravel how tissue injury signals to pain-sensing neurons. If we can understand this at the molecular and cellular level, we can then identify novel pain-killing targets.”

Bhattacharjee and first author Rasheen Powell, PhD, who earned his doctorate from UB in August, discovered that in order to signal pain, a specific type of pain neuron requires endocytosis, the process by which cells engulf external materials or materials at the membrane. Those neurons, called calcitonin-gene related peptide (CGRP)-containing pain neurons, preferentially express a specific endocytosis subunit called AP2A2, which other sensory neurons do not.

“This finding is particularly exciting because a specific subset of pain neurons in the dorsal root ganglia (DRG) in the peripheral nervous system expresses AP2A2 while other populations of sensory neurons in the DRG do not,” said Powell, now a postdoctoral fellow in the Department of Neurology at Harvard Medical School. “This suggests that this subunit has an important role in these particular pain neurons, which are responsible for a majority of inflammatory pain behaviors observed in rodents and humans.”

Using genetic and pharmacological approaches, the researchers found that endocytosis in these neurons was essential for both the development and maintenance of inflammatory pain.

Profound pain reduction

“But when we inhibit endocytosis with either a genetic or pharmacological approach, we observe profound reductions in behaviors indicative of pain,” Powell said.

Even under conditions that promote hyperactivity in pain neurons, the researchers found they could significantly reduce this hyperactivity — and therefore pain perception — when they prevented endocytosis with their novel peptide molecule.

“By inhibiting endocytosis, we are able to prevent pain-sensing neurons from relaying pain information to the central nervous system,” said Powell.

Local advantage

A key advantage of the peptides the researchers developed is that they disrupt endocytosis when applied locally at pain nerve endings.

“In clinical practice, we use local approaches all the time to block pain,” said Bhattacharjee. “Anesthetics are effective at blocking pain but the problem is, they block all sensory neurons, so the patient feels numb, and they are very short-lived. After the anesthetic wears off in a few hours, painkillers are often needed.

“We found that when locally applied, our peptide decreased pain behaviors in multiple inflammatory pain models for up to six days,” he said.

The advantage of locally delivered drugs is that most adverse side effects are avoided, especially the risk of addiction. Adverse side effects are also a key reason why new drugs often fail to get U.S. Food and Drug Administration approval; local delivery of drugs avoids that downside.

Bhattacharjee noted that local delivery of drugs can, however, have their own limitations: They tend to diffuse away quickly from the site where they were administrated. “Our novel technology seems to solve this problem by getting into nerve endings and staying there,” he said. “The result is a long-lasting reduction in pain behavior.”

Gender differences in pain

The UB research also underscored that males and females experience pain differently. In animal studies they conducted, if pain was already established, females did not respond as well to the peptide compared to males. But if the peptide was administered right at the time of injury, females had a much better reduction in pain behavior than their male counterparts did.

“These data follow human clinical studies,” said Bhattacharjee, “where there is a sex difference in both the prevalence and intensity of chronic inflammatory and post-operative pain in humans. This underscores the importance of gender considerations in analgesic development.”

The researchers plan to focus on key preclinical formulation and toxicology studies to enable a new Investigational Drug Application for human testing.

Reference: “Inhibiting endocytosis in CGRP+ nociceptors attenuates inflammatory pain-like behavior” by Rasheen Powell, Violet A. Young, Kerri D. Pryce, Garrett D. Sheehan, Kwaku Bonsu, Abdulelah Ahmed and Arin Bhattacharjee, 4 October 2021, Nature Communications.
DOI: 10.1038/s41467-021-26100-6

Co-authors with Bhattacharjee and Powell are Kerri D. Pryce, Kwaku Bonsu and Abduleh Amhed of the Department of Pharmacology and Toxicology, and Garrett Sheehan and Violet A. Young in the program in neuroscience, all at the Jacobs School.

The work was funded by the National Institutes of Health.

13 Comments on "Long-Lasting Pain Relief Without Opioids: New Local Treatment for Chronic Pain"

  1. Teresa Brewer | October 5, 2021 at 7:33 am | Reply

    Good Morning!

    I’ve read your articles and wondering if your procedures would help with chronic pain for Retroperitoneal Fibrosis patients?

    Please let me know! I’ve been in major chronic pain since the Retroperitoneal Fibrosis was found in 2003!

    You may contact me be phone at 870-715-0638 or email: [email protected].

    Have a wonderful week!

    Teresa Brewer

  2. Would this help for conditions like neuropathy or fibromyalgia? I’m a female and have both.

  3. I have multiple chronic pain areas originally caused by Ankylosing Spondylitis diagnosed in 1979. You name an opiate I’ve been there done that. However, 3 1/2 years ago the Veterans Administration attached/implanted a Dorsal Root Ganglion Stimulator and it has greatly reduced my perception of pain from my waist down! Probably in the not so distant future, my stimulator battery will quit and I will again have to undergo surgery to remove old stimulator and Ganglion root connectors and replant/redo this technology.

    This study has given me some hope for a possibly better pain management future! Thank you BU for this tasty of sunshine!

  4. Michael Mulloy | October 5, 2021 at 11:25 am | Reply

    What about ppl who suffer from fibromyalgia

  5. Candice Hawkins | October 5, 2021 at 4:44 pm | Reply

    You did not indicate whether your procedure works on patients who suffer from long term pain issues.

  6. Could this do the same work as tramadol?

  7. Has anyone had this done, I’d like to have it done also

  8. I am very interested

  9. You mention “hyperactivity in pain neurons”. I would be interested in exploring this with my seronegative Stiff Person Syndrome as it causes hypersensitivity to the slightest of sensory actions. Being a rare disorder, there are very few treatment options available. But being an even more rare version of that rare disorder (approximately 20% +/-) are seronegative or anti-GAD negative. Add Rx allergies, adverse reactions and paradoxical effects of medication…something like this may help many if us. Thank you for your time and efforts!

  10. Susan Karen Clark | October 6, 2021 at 9:27 am | Reply

    I have tried everything and the only thing that works for me is pain pills. But unfortunately, the government has scared the doctors so much they won’t give out any pain meds. So now I suffer 24/7 in pain. It’s ridiculous and against doctors oath.

  11. Dan thinks that there to be a way to submit all chronic pain conditions to see if you can provide home treatment for people who can’t pay you by all our money and maybe find you didn’t help enough

  12. Rachel Peeples | October 6, 2021 at 6:29 pm | Reply

    I am so glad to read about this study. I also suffer from Fibromyalgia and Sarcoidosis. It’s a double whammy when it comes to pain. I’ve been wanting to try something besides Opiods for years. I am wondering what side affects have the study shown so far? Really , Really interested!

  13. I have terrible neuropathy can this help me

Leave a comment

Email address is optional. If provided, your email will not be published or shared.